AstraZeneca PLC (AZN)vsTscan Therapeutics Inc (TCRX)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
TCRX
Tscan Therapeutics Inc
$1.15
-8.73%
HEALTHCARE · Cap: $75.73M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 568801% more annual revenue ($58.74B vs $10.32M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TCRX
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-23.1%
Fair Value
$0.79
Current Price
$1.15
$0.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Revenue surging 286.0% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -71.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book, Revenue Growth. Revenue growth of 286.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : TCRX
The primary concerns for TCRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while TCRX is a hypergrowth play — different risk/reward profiles.
TCRX carries more volatility with a beta of 1.01 — expect wider price swings.
TCRX is growing revenue faster at 286.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 40/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company committed to revolutionizing cancer treatment through its advanced T cell receptor (TCR) discovery platform, which targets specific cancer antigens for precision immunotherapy solutions. The firm’s innovative approach aims to translate cutting-edge scientific research into effective TCR-based therapeutics, enhancing treatment options for a variety of malignancies. With a robust pipeline and a solid intellectual property portfolio, Tscan Therapeutics is strategically positioned to become a key player in the fast-growing sector of T cell-based cancer therapies, addressing significant unmet medical needs and improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?